No abandonment of drug price reviews in FTA negotiation.

Rep. Kim Seon-mi, a member of the National Assembly Health and Welfare Committee, raised a hard question in the parliamentary inquiry to the government administrations on April 13 especially against the descriptions disclosed in the U. S. CSR report covering that the Korean government gave up the drug price review system.

She claimed in the interpellation meeting "Up until 2004 the issue of...